Literature DB >> 2600001

Antibiotic exposure delays intestinal colonization by Clostridium difficile in the newborn.

A F Holton1, M A Hall, J A Lowes.   

Abstract

Two antibiotic regimens commonly used in neonatal intensive care were compared for the rate at which Clostridium difficile appeared in the faeces. Over a nine month period neonates with suspected sepsis admitted to a Special Care Baby Unit (SCBU) were randomly allocated to receive either cefotaxime or penicillin and netilmicin. A contemporaneous group also admitted to SCBU but without sepsis served as non-treated controls. Four hundred and sixteen stool specimens from 158 neonates without diarrhoea were analysed every five to seven days until discharge. The results showed that these antibiotics did not encourage gut colonization by C. difficile, that they might even be protective in this respect and that monotherapy with cefotaxime was no more likely to generate C. difficile overgrowth than the penicillin-aminoglycoside regimen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2600001     DOI: 10.1093/jac/24.5.811

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Gut microbial translocation in critically ill children and effects of supplementation with pre- and pro biotics.

Authors:  Paola Papoff; Giancarlo Ceccarelli; Gabriella d'Ettorre; Carla Cerasaro; Elena Caresta; Fabio Midulla; Corrado Moretti
Journal:  Int J Microbiol       Date:  2012-08-15

Review 2.  The role of Clostridium difficile in the paediatric and neonatal gut - a narrative review.

Authors:  E A Lees; F Miyajima; M Pirmohamed; E D Carrol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-23       Impact factor: 3.267

3.  Detection of Clostridioides difficile toxin B gene: benefits of identifying gastrointestinal pathogens by mPCR assay in the diagnosis of diarrhea in pediatric patients.

Authors:  Jung-Hyun Byun; Dongeun Yong; Heejung Kim
Journal:  BMC Infect Dis       Date:  2022-02-05       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.